{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:35:46Z","timestamp":1793360146371,"version":"4.5.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin-6 (IL-6) plays a pivotal regulatory role in prostate cancer progression, contributing to therapy resistance and reshaping of the tumor microenvironment. This review outlines the clinical relevance of IL-6 as a potential prognostic biomarker and describes its mechanistic involvement in the development of castration resistance, with emphasis on its interplay with distinct cancer-associated fibroblast (CAF) subtypes. Elevated serum IL-6 levels in metastatic castration-resistant prostate cancer are associated with poor responses to docetaxel, enzalutamide, or abiraterone, and correlate with worse prognosis. Mechanistically, IL-6 promotes neuroendocrine differentiation and sustains cell survival under therapeutic stress through activation of signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase (MAPK), and androgen receptor signaling pathways. Recent single-cell studies reveal that prostate CAFs are highly heterogeneous. Certain subtypes are linked to extracellular matrix remodeling and fibrosis, while others exhibit inflammatory or immune-modulatory characteristics, differentially influencing tumor evolution. Specific CAF subsets have been strongly implicated in promoting castration resistance and adverse outcomes. Therapeutic strategies targeting the IL-6\/IL-6R axis\u2014such as neutralizing antibodies, advanced chimeric antigen receptor (CAR)-T designs, and combination regimens\u2014are under active investigation. Simultaneously, modulating CAF plasticity to convert tumor-promoting phenotypes into tumor-restraining ones represents a promising therapeutic avenue. A deeper understanding of IL-6 functions across CAF subtypes may unlock novel precision therapy opportunities for prostate cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1736606","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:27:55Z","timestamp":1768458475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["IL-6\/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Tao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Fan","sequence":"additional","affiliation":[{"name":"Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunhong","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Urology, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nursing Department, Santai Hospital Affiliated to North Sichuan Medical College","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.3390\/cancers15205047","article-title":"Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-55617-4_1","article-title":"Interleukin-6 function and targeting in prostate cancer","volume":"1290","author":"Culig","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-2767","article-title":"Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity","volume":"12","author":"Domingo-Domenech","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1359-6101(00)00021-6","article-title":"Interleukin-6 and prostate cancer progression","volume":"12","author":"Smith","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9070-2","article-title":"Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C","volume":"26","author":"Tumminello","year":"2009","journal-title":"Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","author":"Heinrich","year":"2003","journal-title":"Biochem J 374(Pt"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119085","article-title":"AMPK\/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells","volume":"1868","author":"Natani","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23015","article-title":"Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition","volume":"75","author":"Liu","year":"2015","journal-title":"Prostate"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-0272-5","article-title":"Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells","volume":"6","author":"Cheteh","year":"2020","journal-title":"Cell Death Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00345-025-05757-4","article-title":"Comparative analysis of the performance of the large language models DeepSeek-V3, DeepSeek-R1, open AI-O3 mini and open AI-O3 mini high in urology","volume":"43","author":"Yan","year":"2025","journal-title":"World J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-24-0932","article-title":"YAP1 inhibition induces phenotype switching of cancer-associated fibroblasts to tumor suppressive in prostate cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133160","article-title":"Identification of cancer-associated fibroblasts subtypes in prostate cancer","volume":"14","author":"Pan","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23929","article-title":"Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment","volume":"80","author":"Vickman","year":"2020","journal-title":"Prostate"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23925","article-title":"Stromal myofibroblasts are drivers of invasive cancer growth","volume":"123","author":"De Wever","year":"2008","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3202","article-title":"Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA\/mTOR\/HIF-1\u03b1 signaling","volume":"47","author":"Du","year":"2015","journal-title":"Int J Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bbrc.2023.02.083","article-title":"Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling","volume":"655","author":"Zhang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/ijms20081831","article-title":"Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and\/or enzalutamide therapy","volume":"20","author":"Pal","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21362","article-title":"The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study","volume":"71","author":"Karkera","year":"2011","journal-title":"Prostate"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00405-z","article-title":"Preclinical development of CD126 CAR-T cells with broad antitumor activity","volume":"11","author":"Mishra","year":"2021","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3892\/or.2022.8349","article-title":"Dual STAT\u22123 and IL\u22126R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL\u22126\/IL\u22126R\/STAT\u22123 axis","volume":"48","author":"M\u00e9ndez-Clemente","year":"2022","journal-title":"Oncol Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-23-2260","article-title":"The critical interplay of CAF plasticity and resistance in prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12935-024-03305-5","article-title":"Comprehensive analyses of the cancer-associated fibroblast subtypes and their score system for prediction of outcomes and immunosuppressive microenvironment in prostate cancer","volume":"24","author":"Gao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12452","article-title":"Inflammation and prostate cancer: the role of interleukin 6 (IL-6)","volume":"113","author":"Nguyen","year":"2014","journal-title":"BJU Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g","article-title":"Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway","volume":"42","author":"Lou","year":"2000","journal-title":"Prostate"},{"key":"B31","article-title":"Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression","volume":"7","author":"Lin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26639","article-title":"Interleukin-6 induced overexpression of valosin-containing protein (VCP)\/p97 is associated with androgen-independent prostate cancer (AIPC) progression","volume":"233","author":"Duscharla","year":"2018","journal-title":"J Cell Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.74","article-title":"Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer","volume":"112","author":"Mahon","year":"2015","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22591","article-title":"Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer","volume":"73","author":"Codony-Servat","year":"2013","journal-title":"Prostate"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.07.1384","article-title":"Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer","volume":"78","author":"Kutikov","year":"2011","journal-title":"Urology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/jcm11102853","article-title":"Metronomic chemotherapy in prostate cancer","volume":"11","author":"Wysocki","year":"2022","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13332","article-title":"Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy","volume":"108","author":"Kitamura","year":"2017","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"T95","DOI":"10.1530\/erc-21-0149","article-title":"The tumor microenvironment and immune responses in prostate cancer patients","volume":"28","author":"Kwon","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-2200","article-title":"A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors","volume":"20","author":"Angevin","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910383416","article-title":"Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth","volume":"1","author":"Chun","year":"2010","journal-title":"Genes Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","article-title":"Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e34611","DOI":"10.1097\/md.0000000000034611","article-title":"Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer","volume":"102","author":"Liu","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102255","article-title":"Heterogeneity of cancer-associated fibroblast subpopulations in prostate cancer: Implications for prognosis and immunotherapy","volume":"52","author":"Ding","year":"2025","journal-title":"Transl Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216244","article-title":"Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer","volume":"566","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1560998","article-title":"Intercellular communication between FAP+ fibroblasts and SPP1+ macrophages in prostate cancer via multi-omics","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-00842-0","article-title":"Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer","volume":"5","author":"Cheng","year":"2025","journal-title":"Nat Aging"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1038\/s41598-023-36125-0","article-title":"Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome","volume":"13","author":"Qian","year":"2023","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05011-7","article-title":"Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing","volume":"149","author":"Li","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.026","article-title":"Interleukin-6 in bone metastasis and cancer progression","volume":"46","author":"Ara","year":"2010","journal-title":"Eur J Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/ol.2023.13749","article-title":"Prostate cancer bone metastases biology and clinical management (Review)","volume":"25","author":"Archer Goode","year":"2023","journal-title":"Oncol Lett"},{"key":"B51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-2005-870525","article-title":"Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells","volume":"37","author":"Tenta","year":"2005","journal-title":"Horm Metab Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2025.13353","article-title":"The impact of inflammation on prostate tumor dynamics: a pathological perspective on prostate cancer and benign prostatic hyperplasia","volume":"97","author":"Syahrir","year":"2025","journal-title":"Arch Ital Urol Androl"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11324","article-title":"The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn","volume":"7","author":"Ho","year":"2016","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"16797","DOI":"10.1038\/s41598-021-96224-8","article-title":"Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy","volume":"11","author":"Khoobchandani","year":"2021","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201573","article-title":"A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts","volume":"14","author":"Ren","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(19991001)41:2<127::aid-pros7>3.0.co;2-h","article-title":"Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer","volume":"41","author":"Drachenberg","year":"1999","journal-title":"Prostate"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-04-1560","article-title":"The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480","volume":"11","author":"George","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J"},{"key":"B61","article-title":"Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor","volume":"58","author":"Hobisch","year":"1998","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006020","article-title":"YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1789441","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1736606\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:56:42Z","timestamp":1771916202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1736606\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2025.1736606"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1736606","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1736606"}}